Transplantation in highly HLA-sensitized patients: challenges and solutions

被引:1
作者
Kim, Irene K. [1 ]
Vo, Ashley [1 ]
Jordan, Stanley C. [1 ]
机构
[1] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Transplant Immunotherapy Program, Los Angeles, CA 90048 USA
关键词
human leukocyte antigen; antibodies; desensitization; high-dose intravenous immunoglobulin; rituximab;
D O I
10.2147/TRRM.S50793
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Despite better understanding of the impact of development of the human leukocyte antigen (HLA) antibody and numerous advancements in immunosuppressive therapy, the ability to successfully transplant highly sensitized patients remains a significant challenge. As the percentage of the waiting list becomes increasingly populated with highly sensitized patients, there is a growing demand for effective strategies to manage these patients. Over the past 20 years, desensitization therapies have been modified and developed, and are mainly utilized at transplant centers that have developed expertise. In addition, recognition that the highly sensitized patient population is disadvantaged on the transplant waiting list has led to recent changes in national kidney allocation policy. Furthermore, creative strategies, such as enrollment of sensitized patients into paired kidney exchange programs, have been developed to find compatible matches for these patients. The goal of this article is to address some of the specific challenges related to transplanting the highly sensitized patient at a high-volume transplant center with experience in desensitization and to review established and emerging solutions to help this patient population.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 46 条
[1]  
[Anonymous], ANN DAT REP
[2]  
Barbosa D, 2013, TRANSPLANTATION
[3]   Ambivalent effect of immunoglobulins on the complement system: Activation versus inhibition [J].
Basta, Milan .
MOLECULAR IMMUNOLOGY, 2008, 45 (16) :4073-4079
[4]   Calculated PRA: Initial Results Show Benefits for Sensitized Patients and a Reduction in Positive Crossmatches [J].
Cecka, J. M. ;
Kucheryavaya, A. Y. ;
Reinsmoen, N. L. ;
Leffell, M. S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (04) :719-724
[5]   Preformed cytotoxic antibodies in potential allograft recipients: Recent data [J].
Cecka, JM ;
Zhang, QH ;
Reed, EF .
HUMAN IMMUNOLOGY, 2005, 66 (04) :343-349
[6]   Therapeutic antibodies for autoimmunity and inflammation [J].
Chan, Andrew C. ;
Carter, Paul J. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :301-316
[7]   THE QUALITY OF LIFE OF PATIENTS WITH END-STAGE RENAL-DISEASE [J].
EVANS, RW ;
MANNINEN, DL ;
GARRISON, LP ;
HART, LG ;
BLAGG, CR ;
GUTMAN, RA ;
HULL, AR ;
LOWRIE, EG .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (09) :553-559
[8]   Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection [J].
Everly, Matthew J. ;
Everly, Jason J. ;
Susskind, Brian ;
Brailey, Paul ;
Arend, Lois J. ;
Alloway, Rita R. ;
Roy-Chaudhury, Prabir ;
Govil, Amit ;
Mogilishetty, Gautham ;
Rike, Adele H. ;
Cardi, Michael ;
Wadih, George ;
Tevar, Amit ;
Woodle, E. Steve .
TRANSPLANTATION, 2008, 86 (12) :1754-1761
[9]   Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients [J].
Gabardi, S. ;
Townsend, K. ;
Martin, S. T. ;
Chandraker, A. .
TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (04) :361-368
[10]   Advances in the understanding of the mechanism of action of IVIg [J].
Hartung, Hans-Peter .
JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 3) :3-6